Consequently, a variety of metrics have been developed to reveal putative neoantigens in tumor genomes, with the most common being peptide–MHC‐binding affinity, peptide–MHC complex stability, peptide agretopicity, foreignness, and mutation expression. Here, HLA-C is linked to neoplasm.